Literature DB >> 33143618

New Insights on Fak and Fak Inhibitors.

Chiara Brullo1, Bruno Tasso1.   

Abstract

BACKGROUND: Focal adhesion kinase (Fak) is a cytoplasmic protein tyrosine kinase overexpressed and activated in different solid cancers; it has shown an important role in metastasis formation, cell migration, invasion and angiogenesis and consequently it has been proposed as a potential target in cancer therapy, particularly in a metastatic phase. In recent years, different investigations have highlighted the importance of new Fak inhibitors as potential anti-cancer drugs, but other studies evidenced its role in different pathologies related to the cardiac function or viral infection.
METHODS: An extensive bibliographic research (104 references) has been done concerning the structure of Fak, its importance in tumor development, but also in other pathologies currently under study. The compounds currently subjected to clinical studies were therefore treated using the appropriate databases. Finally, the main chemical scaffolds currently under preclinical investigation were analyzed, focusing on their molecular structures and on the activity structure relationships (SAR).
RESULTS: At the moment, only a few reversible ATP-competitive inhibitors are under investigation in pre-clinical studies and clinical trials. Other compounds, with different chemical scaffolds, are investigated to obtain more active and selective Fak inhibitors. This mini-review is a summary of different Fak functions in cancer and other pathologies; the compounds today in clinical trials and the recent chemical scaffolds (also included in patents) giving the most interesting results are investigated. In addition, PROTAC molecules are reported.
CONCLUSION: All reported results evidenced that additional studies are necessary to design and synthesize new selective and more active compounds, although promising information has been obtained from associations between Fak inhibitors and other different anti- cancer drugs. In addition, the other important roles evidenced, both at the nuclear level and in non-cancerous cells, make this protein an increasingly important target in pharmaceutical chemistry. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Fak inhibitors; Focal adhesion kinase; PROTACS; cancer therapy; clinical trials; metastasis

Mesh:

Substances:

Year:  2021        PMID: 33143618     DOI: 10.2174/0929867327666201103162239

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  6 in total

Review 1.  The Development of FAK Inhibitors: A Five-Year Update.

Authors:  Andrea Spallarossa; Bruno Tasso; Eleonora Russo; Carla Villa; Chiara Brullo
Journal:  Int J Mol Sci       Date:  2022-06-07       Impact factor: 6.208

2.  Overexpression of GATA5 Inhibits Prostate Cancer Progression by Regulating PLAGL2 via the FAK/PI3K/AKT Pathway.

Authors:  Qinghua Wang; Zelin Liu; Guanzhong Zhai; Xi Yu; Shuai Ke; Haoren Shao; Jia Guo
Journal:  Cancers (Basel)       Date:  2022-04-21       Impact factor: 6.575

Review 3.  Focal adhesion kinase inhibitors, a heavy punch to cancer.

Authors:  Yueling Wu; Ning Li; Chengfeng Ye; Xingmei Jiang; Hui Luo; Baoyuan Zhang; Ying Zhang; Qingyu Zhang
Journal:  Discov Oncol       Date:  2021-11-22

Review 4.  The Development of BTK Inhibitors: A Five-Year Update.

Authors:  Bruno Tasso; Andrea Spallarossa; Eleonora Russo; Chiara Brullo
Journal:  Molecules       Date:  2021-12-06       Impact factor: 4.411

5.  Downregulation of MicroRNA-1 and Its Potential Molecular Mechanism in Nasopharyngeal Cancer: An Investigation Combined with In Silico and In-House Immunohistochemistry Validation.

Authors:  Jia-Ying Wen; Li-Ting Qin; Gang Chen; He-Qing Huang; Ming-Jun Shen; Jin-Shu Pang; Yu-Xing Tang; Wei Lu; Ren-Sheng Wang; Jia-Yuan Luo
Journal:  Dis Markers       Date:  2022-02-25       Impact factor: 3.434

6.  FAM107A Inactivation Associated with Promoter Methylation Affects Prostate Cancer Progression through the FAK/PI3K/AKT Pathway.

Authors:  Shuai Ke; Zelin Liu; Qinghua Wang; Guanzhong Zhai; Haoren Shao; Xi Yu; Jia Guo
Journal:  Cancers (Basel)       Date:  2022-08-13       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.